Lastly, enoblituzumab, a humanized, Fc-engineered mAb binding CD276 has recently been investigated both as single-agent as well as in combination with pembrolizumab in a phase 1 trial in HNSCC, resulting in sustained inhibition of tumor growth (68–70). The gene discussed is CD276; the disease is neoplasm.